Marco Astegiano
5PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Nov 19, 2020
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept.Davide Giuseppe Ribaldone, Marta Vernero, Marco Astegiano
|Feb 15, 2020
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Rinaldo Pellicano
|Dec 12, 2019
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis.Davide Giuseppe Ribaldone, Rinaldo Pellicano, Giorgio Maria Saracco
|Nov 07, 2019
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index.Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Rinaldo Pellicano
|Sep 25, 2019
Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients.Davide Giuseppe Ribaldone, Marta Vernero, Simone Parisi
Pageof 1
